ALLINIs modulate the interaction between HIV-1 Rev and integrase

Size: px
Start display at page:

Download "ALLINIs modulate the interaction between HIV-1 Rev and integrase"

Transcription

1 ALLINIs modulate the interaction between HIV-1 Rev and integrase Date: 13 June 2017 Author Shaakira Abrahams Salerwe Mosebi, Qasim Fish, Raymond Hewer, Maria Papathanasopoulos

2 Outline Background Results and discussion In vitro selection studies selected by ALLINIs The interaction between Rev and integrase in the presence of ALLINNIs The effect of ALLINIs and Rev on multimerization of integrase Conclusion Acknowledgements

3 Background HIV-1 Rev regulates the integration step by inhibiting integration Integrase (IN) forms part of the pre-integration complex that comprise LEDGF/p75, viral DNA and viral accessory proteins Highly dependent on the equilibrium state of IN dimer LEDGF/p75 binds to the hydrophobic pocket of the IN dimer interface Rev Binds to the LEDGF/p75 interface - Interplay between IN, LEDGF/p75 and Rev for the IN dimer interface Rev inhibits integration through multimerization

4 Background: ALLINIs Allosteric IN inhibitors (ALLINIs): Allosterically inhibit the catalytic activities of IN Interplay between ALLINIs and LEDGF/p75 for dimerization interface of IN Mechanism of action: Shifts oligomerization of IN into an inactive multimeric form Produces defective and less infectious virions ALLINIs used in this study: CX05168, Christ et al, 2010 and Mut 101, Le Rouzic, 2013

5 Background ALLINIs and Rev effect the HIV-1 integration step in a similar manner Interplay between Rev and LEDGF/p75; Interplay between ALLINIs and LEDGF/p75 Multimerization of IN Prevents IN from binding to host DNA Hypothesis: ALLINIs modulate Rev s regulatory role in HIV-1 integration Objectives 1. Select mutations in the pol and rev gene using ALLINIs 2. Determine the binding interaction of Rev and IN in the presence of ALLINIs 3. Determine whether the Rev-driven multimerization is modulated by ALLINIs

6 Results and discussion 1. Select mutations in the pol gene using ALLINIs 2. Determine the binding interaction of Rev and IN in the presence of ALLINIs 3. Determine whether the Rev-driven multimerization is modulated by ALLINIs

7 In vitro selection studies Figure 1: Viral fitness of FV 26 and FV 3 in vitro selected by Mut 101 and CX05168

8 EC 50 of CX05168 against HIV-1 primary Subtype C EC 50 of CX05168 against FV 3 and FV 26 higher than Subtype B NL4-3 EC 50 = 2.35µM (Christ et al, 2010) FV 3 EC 50 = 4.3 ± 0.4µM FV 26 EC 50 = 40.7 ± 0.8µM Polymorphic mutations found in drug naïve FV3 and FV 26 FV 3 FV 26 L101F T218I A265V I84M L101Y K215N * *

9 Phenotypic susceptibility associated with mutations selected by Mut 101 Conducted an antiviral assay using Mut 101 FV Passage EC 50 ± SD Fold change Possible (µm) mutation Drug 0.48 ± 0.15 naïve 8 ND H171L Drug 0.53 ± 0.01 naïve ± fold reduction L172I ± fold increase L172I K215D 41 ND H171Q I84M; L101Y; K215N

10 Results and discussion 1. Select mutations in the pol and rev gene using ALLINIs 2. Determine the binding interaction of Rev and IN in the presence of ALLINIs 3. Determine whether the Rev-driven multimerization is modulated by ALLINIs

11 Incubation of IN with ALLINIs then Rev * IN + Rev IN + Mut 101/CX Rev IN + Rev + Mut 101/CX05168 K d Rev IN is significantly lower than the K d of Rev IN in the presence of Mut 101 and CX05168 when incubating IN with ALLINI first then incubating with Rev Suggest that Mut 101 and CX05168 decreases the interaction between Rev and IN CX05168 displaces Ala128 on IN to which Rev binds Mut 101 alters alpha helices of IN (res and ) rev is unable to bind

12 Interaction of IN with Rev then ALLINIs * K d of Rev IN not significantly different to K d of Rev- IN when incubating IN and Rev followed by ALLINIs ALLINIs do not interfere with the Rev IN interaction once Rev is bound to IN Rev masks the interaction site of Mut 101(res 174) and CX05168 (res 128) to IN

13 Results and discussion 1. Select mutations in the pol and rev gene using ALLINIs 2. Determine the binding interaction of Rev and IN in the presence of ALLINIs 3. Determine whether the Rev-driven multimerization is modulated by ALLINIs

14 Multimerization of IN induced by ALLINIs and Rev Multimerization of IN was determined through AlphaScreen dimerization assay Multimerization of IN: Mut 101 > CX05168 > Rev

15 Rev decreases ALLINI induced multimerization of IN Rev reverse multimerization of IN induced by ALLINIs Phenomenon is observed by LEDGF/p75 and ALLINIs (Feng at al, 2016) LEDGF/p75 and ALLINIs have different multimerization patterns LEDGF/p75: NTD-CCD ALINIs: CCD-CCD Propose that Rev induces multimerization in a similar manner as LEDGF/p75 consequently reversing multimerization of IN induced by Mut 101 and CX05168

16 Conclusion Mut 101 resistant phenotype was observed through an EC 50 shift while CX05168 was not as effective against HIV-1 Subtype C FV 3 and FV 26 strains as Subtype B The behaviour of Rev and ALLINIs in the integration step are modulated when combined

17 Acknowledgements Dr Salerwe Mosebi Mintek Dr Raymond Hewer (UKZN) Prof Maria Papathanasopoulos (Wits - HIV Pathogenesis Research Unit) Mr. Qasim Fish Ms. Angela Harrison Mintek Centre of Metal Based Drug Discovery (CMDD) NRF PDP Scholarship

18 Thank You

PREDICTING SUSCEPTIBILITY AND RESISTANCE FOR HEPATITIS B VIRUS CAPSID ASSEMBLY EFFECTORS

PREDICTING SUSCEPTIBILITY AND RESISTANCE FOR HEPATITIS B VIRUS CAPSID ASSEMBLY EFFECTORS PREDICTING SUSCEPTIBILITY AND RESISTANCE FOR HEPATITIS B VIRUS CAPSID ASSEMBLY EFFECTORS BRYAN D. COX, PH.D. EMORY UNIVERSITY, DEPARTMENT OF PEDIATRICS LABORATORY OF BIOCHEMICAL PHARMACOLOGY EMORY CENTER

More information

The HIV life cycle. integration. virus production. entry. transcription. reverse transcription. nuclear import

The HIV life cycle. integration. virus production. entry. transcription. reverse transcription. nuclear import The HIV life cycle entry reverse transcription transcription integration virus production nuclear import Hazuda 2012 Integration Insertion of the viral DNA into host chromosomal DNA, essential step in

More information

Towards a block and lock strategy: LEDGINs hamper the establishment of a reactivation competent HIV reservoir.

Towards a block and lock strategy: LEDGINs hamper the establishment of a reactivation competent HIV reservoir. Abstract no. MOLBPEA13 Towards a block and lock strategy: LEDGINs hamper the establishment of a reactivation competent HIV reservoir. G. Vansant,,A. Bruggemans, L. Vranckx, S. Saleh, I. Zurnic, F. Christ,

More information

ARV Mode of Action. Mode of Action. Mode of Action NRTI. Immunopaedia.org.za

ARV Mode of Action. Mode of Action. Mode of Action NRTI. Immunopaedia.org.za ARV Mode of Action Mode of Action Mode of Action - NRTI Mode of Action - NNRTI Mode of Action - Protease Inhibitors Mode of Action - Integrase inhibitor Mode of Action - Entry Inhibitors Mode of Action

More information

Integrase strand-transfer inhibitors primary resistance in patients with acute/recent HIV infection

Integrase strand-transfer inhibitors primary resistance in patients with acute/recent HIV infection Integrase strand-transfer inhibitors primary resistance in patients with acute/recent HIV infection Juan Ambrosioni, David Nicolás, Christian Manzardo, Fernando Agüero, José Luis Blanco, Maria del Mar

More information

Conference Reports for NATAP. S/GSK Integrase Inhibitor Resistance Profile

Conference Reports for NATAP. S/GSK Integrase Inhibitor Resistance Profile Conference Reports for NATAP EACS - 12th European AIDS Conference November 11-14, 2009 Cologne, Germany Back S/GSK1349572 Integrase Inhibitor Resistance Profile Reported by Jules Levin EACS Oct 31-Nov

More information

LEDGINs inhibit late stage HIV-1 replication by modulating integrase multimerization in the virions

LEDGINs inhibit late stage HIV-1 replication by modulating integrase multimerization in the virions Desimmie et al. Retrovirology 2013, 10:57 RESEARCH Open Access LEDGINs inhibit late stage HIV-1 replication by modulating integrase multimerization in the virions Belete Ayele Desimmie 1, Rik Schrijvers

More information

STRUCTURAL STUDIES OF THE HIV-1 PRE-INTEGRATION COMPLEX IN/LEDGF INTERACTION INHIBITORS

STRUCTURAL STUDIES OF THE HIV-1 PRE-INTEGRATION COMPLEX IN/LEDGF INTERACTION INHIBITORS STRUCTURAL STUDIES OF THE HIV-1 PRE-INTEGRATION COMPLEX IN/LEDGF INTERACTION INHIBITORS Marc Ruff Laboratory of Integrated structural biology IGBMC, Illkirch, France ruff@igbmc.fr Schematic diagram of

More information

Retrovirology. Open Access RESEARCH

Retrovirology. Open Access RESEARCH DOI 1.1186/s12977-17-373-2 Retrovirology RESEARCH Open Access The HIV 1 integrase LEDGF allosteric inhibitor MUT A: resistance profile, impairment of virus maturation and infectivity but without influence

More information

Identification and Evaluation of Inhibitors Targeting the HIV-1 Integrase-LEDGF/p75 Interaction

Identification and Evaluation of Inhibitors Targeting the HIV-1 Integrase-LEDGF/p75 Interaction Identification and Evaluation of Inhibitors Targeting the HIV-1 Integrase-LEDGF/p75 Interaction By Angela Theresa Harrison A dissertation submitted to the Faculty of Health Sciences, University of the

More information

Dr. Ahmed K. Ali. Outcomes of the virus infection for the host

Dr. Ahmed K. Ali. Outcomes of the virus infection for the host Lec. 9 Dr. Ahmed K. Ali Outcomes of the virus infection for the host In the previous few chapters we have looked at aspects of the virus replication cycle that culminate in the exit of infective progeny

More information

Lentiviruses: HIV-1 Pathogenesis

Lentiviruses: HIV-1 Pathogenesis Lentiviruses: HIV-1 Pathogenesis Human Immunodeficiency Virus, HIV, computer graphic by Russell Kightley Tsafi Pe ery, Ph.D. Departments of Medicine and Biochemistry & Molecular Biology NJMS, UMDNJ. e-mail:

More information

LESSON 4.4 WORKBOOK. How viruses make us sick: Viral Replication

LESSON 4.4 WORKBOOK. How viruses make us sick: Viral Replication DEFINITIONS OF TERMS Eukaryotic: Non-bacterial cell type (bacteria are prokaryotes).. LESSON 4.4 WORKBOOK How viruses make us sick: Viral Replication This lesson extends the principles we learned in Unit

More information

The mechanism of H171T resistance reveals the importance of Nδ-protonated. for the binding of allosteric inhibitor BI-D to HIV-1 integrase.

The mechanism of H171T resistance reveals the importance of Nδ-protonated. for the binding of allosteric inhibitor BI-D to HIV-1 integrase. The mechanism of H171T resistance reveals the importance of Nδ-protonated His171 for the binding of allosteric inhibitor BI-D to HIV-1 integrase The Harvard community has made this article openly available.

More information

Evaluation and Management of Virologic Failure

Evaluation and Management of Virologic Failure National HIV Curriculum PDF created November 3, 2018, 12:26 am Evaluation and Management of Virologic Failure This is a PDF version of the following document: Section 1: Antiretroviral Therapy Topic 5:

More information

Resistance to Integrase Strand Transfer Inhibitors

Resistance to Integrase Strand Transfer Inhibitors NORTHWEST AIDS EDUCATION AND TRAINING CENTER Resistance to Integrase Strand Transfer Inhibitors David Spach, MD Clinical Director, Northwest AETC Professor of Medicine, Division of Infectious Diseases

More information

modified dye uptake assay including formazan test EC 90 not tested plaque reduction assay

modified dye uptake assay including formazan test EC 90 not tested plaque reduction assay Sauerbrei A, Bohn-Wippert K, Kaspar M, Krumbholz A, Karrasch M, Zell R. 2015. Database on natural polymorphisms and resistance-related non-synonymous mutations in thymidine kinase and DNA polymerase genes

More information

The E138A substitution in HIV-1 reverse transcriptase decreases in vitro. susceptibility to emtricitabine as indicated by competitive fitness assays

The E138A substitution in HIV-1 reverse transcriptase decreases in vitro. susceptibility to emtricitabine as indicated by competitive fitness assays AAC Accepts, published online ahead of print on 13 January 2014 Antimicrob. Agents Chemother. doi:10.1128/aac.02114-13 Copyright 2014, American Society for Microbiology. All Rights Reserved. 1 2 The E138A

More information

Case Study. Dr Sarah Sasson Immunopathology Registrar. HIV, Immunology and Infectious Diseases Department and SydPath, St Vincent's Hospital.

Case Study. Dr Sarah Sasson Immunopathology Registrar. HIV, Immunology and Infectious Diseases Department and SydPath, St Vincent's Hospital. Case Study Dr Sarah Sasson Immunopathology Registrar HIV, Immunology and Infectious Diseases Department and SydPath, St Vincent's Hospital Case 1: Case 1: 45F in Cameroon Cameroon HIV+ Presents with cutaneous

More information

ACCELERATED COMMUNICATIONS

ACCELERATED COMMUNICATIONS ACCELERATED COMMUNICATIONS Allosteric HIV-1 integrase inhibitors promote aberrant protein multimerization by directly mediating inter-subunit interactions: Structural and thermodynamic modeling studies

More information

Molecular Dynamics of HIV-1 Reverse Transcriptase

Molecular Dynamics of HIV-1 Reverse Transcriptase Molecular Dynamics of HIV-1 Reverse Transcriptase Abderrahmane Benghanem Rensselaer Polytechnic Institute,Troy, NY Mentor: Dr. Maria Kurnikova Carnegie Mellon, Pittsburgh PA Outline HIV-1 Reverse Transcriptase

More information

HIV acute infections and elite controllers- what can we learn?

HIV acute infections and elite controllers- what can we learn? HIV acute infections and elite controllers- what can we learn? Thumbi Ndung u, BVM, PhD KwaZulu-Natal Research Institute for Tuberculosis and HIV (K-RITH) and HIV Pathogenesis Programme (HPP), Doris Duke

More information

Antiviral Activity of Tenofovir Alafenamide against HIV-1 with Thymidine Analog Mutation(s) and M184V

Antiviral Activity of Tenofovir Alafenamide against HIV-1 with Thymidine Analog Mutation(s) and M184V Antiviral Activity of Tenofovir Alafenamide against HIV-1 with Thymidine Analog Mutation(s) and M184V Christian Callebaut, PhD Gilead Sciences, Foster City, CA, USA HIV DART AND EMERGING VIRUSES 12/08/2016

More information

On an individual level. Time since infection. NEJM, April HIV-1 evolution in response to immune selection pressures

On an individual level. Time since infection. NEJM, April HIV-1 evolution in response to immune selection pressures HIV-1 evolution in response to immune selection pressures BISC 441 guest lecture Zabrina Brumme, Ph.D. Assistant Professor, Faculty of Health Sciences Simon Fraser University http://www3.niaid.nih.gov/topics/hivaids/understanding/biology/structure.htm

More information

INI1/hSNF5-interaction defective HIV-1 IN mutants exhibit impaired particle morphology, reverse transcription and integration in vivo

INI1/hSNF5-interaction defective HIV-1 IN mutants exhibit impaired particle morphology, reverse transcription and integration in vivo Mathew et al. Retrovirology 213, 1:66 RESEARCH Open Access INI1/hSNF5-interaction defective HIV-1 IN mutants exhibit impaired particle morphology, reverse transcription and integration in vivo Sheeba Mathew

More information

Retroviruses. ---The name retrovirus comes from the enzyme, reverse transcriptase.

Retroviruses. ---The name retrovirus comes from the enzyme, reverse transcriptase. Retroviruses ---The name retrovirus comes from the enzyme, reverse transcriptase. ---Reverse transcriptase (RT) converts the RNA genome present in the virus particle into DNA. ---RT discovered in 1970.

More information

Molecular Medicine: Gleevec and Chronic Myelogenous Leukemia

Molecular Medicine: Gleevec and Chronic Myelogenous Leukemia Molecular Medicine: Gleevec and Chronic Myelogenous Leukemia Dec 14 & 19, 2006 Prof. Erin Shea Prof. Dan Kahne Cancer, Kinases and Gleevec: 1. What is CML? a. Blood cell maturation b. Philadelphia Chromosome

More information

Reverse transcriptase and protease inhibitor resistant mutations in art treatment naïve and treated hiv-1 infected children in India A Short Review

Reverse transcriptase and protease inhibitor resistant mutations in art treatment naïve and treated hiv-1 infected children in India A Short Review pissn 2349-2910 eissn 2395-0684 REVIEW Reverse transcriptase and protease inhibitor resistant mutations in art treatment naïve and treated hiv-1 infected children in India A Short Review Dinesh Bure, Department

More information

Monitoring for Drug Resistance by Genotyping. Urvi M Parikh, PhD MTN Virology Core Lab

Monitoring for Drug Resistance by Genotyping. Urvi M Parikh, PhD MTN Virology Core Lab Monitoring for Drug Resistance by Genotyping Urvi M Parikh, PhD MTN Virology Core Lab Outline What is Drug Resistance? Genotyping Algorithm Standard vs Sensitive Resistance Testing Sequencing Protocols

More information

Patricia Fitzgerald-Bocarsly

Patricia Fitzgerald-Bocarsly FLU Patricia Fitzgerald-Bocarsly October 23, 2008 Orthomyxoviruses Orthomyxo virus (ortho = true or correct ) Negative-sense RNA virus (complementary to mrna) Five different genera Influenza A, B, C Thogotovirus

More information

HIV-1 Subtypes: An Overview. Anna Maria Geretti Royal Free Hospital

HIV-1 Subtypes: An Overview. Anna Maria Geretti Royal Free Hospital HIV-1 Subtypes: An Overview Anna Maria Geretti Royal Free Hospital Group M Subtypes A (1, 2, 3) B C D F (1, 2) G H J K Mechanisms of HIV-1 genetic diversification Point mutations RT error rate: ~1 per

More information

Modeling the HIV-1 Intasome: A Prototype View of the Target of Integrase Inhibitors

Modeling the HIV-1 Intasome: A Prototype View of the Target of Integrase Inhibitors Viruses 2010, 2, 2777-2781; doi:10.3390/v2122777 OPEN ACCESS viruses ISSN 1999-4915 www.mdpi.com/journal/viruses Commentary Modeling the HIV-1 Intasome: A Prototype View of the Target of Integrase Inhibitors

More information

Clinical utility of NGS for the detection of HIV and HCV resistance

Clinical utility of NGS for the detection of HIV and HCV resistance 18 th Annual Resistance and Antiviral Therapy Meeting v Professor Janke Schinkel Academic Medical Centre, Amsterdam, The Netherlands Thursday 18 September 2014, Royal College of Physicians, London Clinical

More information

Analysis of Resistance to Human Immunodeficiency Virus Protease Inhibitors Using Molecular Mechanics and Machine Learning Strategies

Analysis of Resistance to Human Immunodeficiency Virus Protease Inhibitors Using Molecular Mechanics and Machine Learning Strategies American Medical Journal 1 (2): 126-132, 2010 ISSN 1949-0070 2010 Science Publications Analysis of Resistance to Human Immunodeficiency Virus Protease Inhibitors Using Molecular Mechanics and Machine Learning

More information

HIV 101: Fundamentals of HIV Infection

HIV 101: Fundamentals of HIV Infection HIV 101: Fundamentals of HIV Infection David H. Spach, MD Professor of Medicine University of Washington Seattle, Washington Learning Objectives After attending this presentation, learners will be able

More information

Virological failure to Protease inhibitors in Monotherapy is linked to the presence of signature mutations in Gag without changes in HIV-1 replication

Virological failure to Protease inhibitors in Monotherapy is linked to the presence of signature mutations in Gag without changes in HIV-1 replication Virological failure to Protease inhibitors in Monotherapy is linked to the presence of signature mutations in Gag without changes in HIV-1 replication Oscar Blanch-Lombarte Rome, 7-9 June, 2017 European

More information

LESSON 4.6 WORKBOOK. Designing an antiviral drug The challenge of HIV

LESSON 4.6 WORKBOOK. Designing an antiviral drug The challenge of HIV LESSON 4.6 WORKBOOK Designing an antiviral drug The challenge of HIV In the last two lessons we discussed the how the viral life cycle causes host cell damage. But is there anything we can do to prevent

More information

Previous Class. Today. Detection of enzymatic intermediates: Protein tyrosine phosphatase mechanism. Protein Kinase Catalytic Properties

Previous Class. Today. Detection of enzymatic intermediates: Protein tyrosine phosphatase mechanism. Protein Kinase Catalytic Properties Previous Class Detection of enzymatic intermediates: Protein tyrosine phosphatase mechanism Today Protein Kinase Catalytic Properties Protein Phosphorylation Phosphorylation: key protein modification

More information

HIV Immunopathogenesis. Modeling the Immune System May 2, 2007

HIV Immunopathogenesis. Modeling the Immune System May 2, 2007 HIV Immunopathogenesis Modeling the Immune System May 2, 2007 Question 1 : Explain how HIV infects the host Zafer Iscan Yuanjian Wang Zufferey Abhishek Garg How does HIV infect the host? HIV infection

More information

VIROLOGY. Engineering Viral Genomes: Retrovirus Vectors

VIROLOGY. Engineering Viral Genomes: Retrovirus Vectors VIROLOGY Engineering Viral Genomes: Retrovirus Vectors Viral vectors Retrovirus replicative cycle Most mammalian retroviruses use trna PRO, trna Lys3, trna Lys1,2 The partially unfolded trna is annealed

More information

Protein Modeling Event

Protein Modeling Event Protein Modeling Event School Name: School Number: Team Member 1: Team Member 2: : Pre-Build Score: On-Site Build Score: Test Score: Tie Breaker: Total: Final Rank: Part I: Pre-Build (40% of total score)

More information

How HIV Causes Disease Prof. Bruce D. Walker

How HIV Causes Disease Prof. Bruce D. Walker How HIV Causes Disease Howard Hughes Medical Institute Massachusetts General Hospital Harvard Medical School 1 The global AIDS crisis 60 million infections 20 million deaths 2 3 The screen versions of

More information

Globular proteins Proteins globular fibrous

Globular proteins Proteins globular fibrous Globular proteins Globular proteins Proteins are biochemical compounds consisting of one or more polypeptides typically folded into a globular or fibrous form in a biologically functional way. Globular

More information

Under the Radar Screen: How Bugs Trick Our Immune Defenses

Under the Radar Screen: How Bugs Trick Our Immune Defenses Under the Radar Screen: How Bugs Trick Our Immune Defenses Session 7: Cytokines Marie-Eve Paquet and Gijsbert Grotenbreg Whitehead Institute for Biomedical Research HHV-8 Discovered in the 1980 s at the

More information

Homework 6 Solutions

Homework 6 Solutions Homework 6 Solutions Math 314, Fall 216 Problem 1 The HIV virus targets CD4+ T cells, sometimes called helper T cells During an infection, the total number T t) of helper T cells in the blood, the number

More information

Antiretroviral Prophylaxis and HIV Drug Resistance. John Mellors University of Pittsburgh

Antiretroviral Prophylaxis and HIV Drug Resistance. John Mellors University of Pittsburgh Antiretroviral Prophylaxis and HIV Drug Resistance John Mellors University of Pittsburgh MTN Annual 2008 Outline Two minutes on terminology Origins of HIV drug resistance Lessons learned from ART Do these

More information

Update on HIV Drug Resistance. Daniel R. Kuritzkes, MD Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School

Update on HIV Drug Resistance. Daniel R. Kuritzkes, MD Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School Update on HIV Drug Resistance Daniel R. Kuritzkes, MD Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School Learning Objectives Upon completion of this presentation, learners

More information

Basis and Clinical Applications of Interferon

Basis and Clinical Applications of Interferon Interferon Therapy Basis and Clinical Applications of Interferon JMAJ 47(1): 7 12, 2004 Jiro IMANISHI Professor, Kyoto Prefectural University of Medicine Abstract: Interferon (IFN) is an antiviral substance

More information

Immunodeficiency. (2 of 2)

Immunodeficiency. (2 of 2) Immunodeficiency (2 of 2) Acquired (secondary) immunodeficiencies More common Many causes such as therapy, cancer, sarcoidosis, malnutrition, infection & renal disease The most common of which is therapy-related

More information

High Failure Rate of the ViroSeq HIV-1 Genotyping System for Drug Resistance Testing in Cameroon, a Country with Broad HIV-1 Genetic Diversity

High Failure Rate of the ViroSeq HIV-1 Genotyping System for Drug Resistance Testing in Cameroon, a Country with Broad HIV-1 Genetic Diversity JOURNAL OF CLINICAL MICROBIOLOGY, Apr. 2011, p. 1635 1641 Vol. 49, No. 4 0095-1137/11/$12.00 doi:10.1128/jcm.01478-10 Copyright 2011, American Society for Microbiology. All Rights Reserved. High Failure

More information

The MOLECULES of LIFE

The MOLECULES of LIFE The MOLECULES of LIFE Physical and Chemical Principles Solutions Manual Prepared by James Fraser and Samuel Leachman Chapter 16 Principles of Enzyme Catalysis Problems True/False and Multiple Choice 1.

More information

Development of an HIV-1 Integrase enzyme strand transfer assay

Development of an HIV-1 Integrase enzyme strand transfer assay Development of an HIV-1 Integrase enzyme strand transfer assay A dissertation submitted to the Faculty of Health Sciences, University of the Witwatersrand, in fulfillment of the requirements for the degree

More information

Micro 301 HIV/AIDS. Since its discovery 31 years ago 12/3/ Acquired Immunodeficiency Syndrome (AIDS) has killed >32 million people

Micro 301 HIV/AIDS. Since its discovery 31 years ago 12/3/ Acquired Immunodeficiency Syndrome (AIDS) has killed >32 million people Micro 301 HIV/AIDS Shiu-Lok Hu hus@uw.edu December 3, 2012 Since its discovery 31 years ago Acquired Immunodeficiency Syndrome (AIDS) has killed >32 million people In 2011 34.0 million [31.4 35.9 million]

More information

Clinical Study Report AI Final 28 Feb Volume: Page:

Clinical Study Report AI Final 28 Feb Volume: Page: Study Design, Continued Electrocardiogram (ECG) and vital sign assessments were done at select times during the study. Blood and urine samples for clinical laboratory evaluations were collected at specified

More information

Human Immunodeficiency Virus

Human Immunodeficiency Virus Human Immunodeficiency Virus Virion Genome Genes and proteins Viruses and hosts Diseases Distinctive characteristics Viruses and hosts Lentivirus from Latin lentis (slow), for slow progression of disease

More information

HIV INFECTION: An Overview

HIV INFECTION: An Overview HIV INFECTION: An Overview UNIVERSITY OF PAPUA NEW GUINEA SCHOOL OF MEDICINE AND HEALTH SCIENCES DIVISION OF BASIC MEDICAL SCIENCES DISCIPLINE OF BIOCHEMISTRY & MOLECULAR BIOLOGY PBL MBBS II SEMINAR VJ

More information

Ebola Virus. Emerging Diseases. Biosciences in the 21 st Century Dr. Amber Rice December 4, 2017

Ebola Virus. Emerging Diseases. Biosciences in the 21 st Century Dr. Amber Rice December 4, 2017 Ebola Virus Emerging Diseases Biosciences in the 21 st Century Dr. Amber Rice December 4, 2017 Outline Disease emergence: a case study How do pathogens shift hosts? Evolution within hosts: The evolution

More information

Fayth K. Yoshimura, Ph.D. September 7, of 7 HIV - BASIC PROPERTIES

Fayth K. Yoshimura, Ph.D. September 7, of 7 HIV - BASIC PROPERTIES 1 of 7 I. Viral Origin. A. Retrovirus - animal lentiviruses. HIV - BASIC PROPERTIES 1. HIV is a member of the Retrovirus family and more specifically it is a member of the Lentivirus genus of this family.

More information

Proteins. These are polymers of 20 common amino acids linked in various sequences. Proteins differ in molecular mass, molecular structure and shape

Proteins. These are polymers of 20 common amino acids linked in various sequences. Proteins differ in molecular mass, molecular structure and shape Proteins These are polymers of 20 common amino acids linked in various sequences. Proteins differ in molecular mass, molecular structure and shape Characteristics if protein Amino acids are linked by covalent

More information

Patterns of hemagglutinin evolution and the epidemiology of influenza

Patterns of hemagglutinin evolution and the epidemiology of influenza 2 8 US Annual Mortality Rate All causes Infectious Disease Patterns of hemagglutinin evolution and the epidemiology of influenza DIMACS Working Group on Genetics and Evolution of Pathogens, 25 Nov 3 Deaths

More information

Nature Medicine: doi: /nm.2109

Nature Medicine: doi: /nm.2109 HIV 1 Infects Multipotent Progenitor Cells Causing Cell Death and Establishing Latent Cellular Reservoirs Christoph C. Carter, Adewunmi Onafuwa Nuga, Lucy A. M c Namara, James Riddell IV, Dale Bixby, Michael

More information

Influenza viruses. Virion. Genome. Genes and proteins. Viruses and hosts. Diseases. Distinctive characteristics

Influenza viruses. Virion. Genome. Genes and proteins. Viruses and hosts. Diseases. Distinctive characteristics Influenza viruses Virion Genome Genes and proteins Viruses and hosts Diseases Distinctive characteristics Virion Enveloped particles, quasi-spherical or filamentous Diameter 80-120 nm Envelope is derived

More information

Changes in CD4+ cells mirna expression following exposure to HIV 1 Claudio Casoli

Changes in CD4+ cells mirna expression following exposure to HIV 1 Claudio Casoli Changes in CD4+ cells mirna expression following exposure to HIV 1 Claudio Casoli University of Milan Rationale There is evidence that mirnas can modulate host innate immunity against viruses. Specifically

More information

VIRTUAL SCREENS WITH MULTIPLE RECEPTOR CONFORMATIONS. Rob Swift, UCI Wednesday, August 3, 2011

VIRTUAL SCREENS WITH MULTIPLE RECEPTOR CONFORMATIONS. Rob Swift, UCI Wednesday, August 3, 2011 VIRTUAL SCREENS WITH MULTIPLE RECEPTR CNFRMATINS Rob Swift, UCI Wednesday, August 3, 2011 utline verview of multi receptor virtual screening in CADD Case studies 1. Trypanosoma brucei RNA editing ligase

More information

Mutants and HBV vaccination. Dr. Ulus Salih Akarca Ege University, Izmir, Turkey

Mutants and HBV vaccination. Dr. Ulus Salih Akarca Ege University, Izmir, Turkey Mutants and HBV vaccination Dr. Ulus Salih Akarca Ege University, Izmir, Turkey Geographic Distribution of Chronic HBV Infection 400 million people are carrier of HBV Leading cause of cirrhosis and HCC

More information

Exploring Energy and Fitness Landscapes of Proteins

Exploring Energy and Fitness Landscapes of Proteins Exploring Energy and Fitness Landscapes of Proteins! Computer Simulations in Chemistry and Biophysics! Protein-Ligand Binding: structure based drug design! HIV Family and Kinase Family Protein Targets!

More information

172R 172K TAM-2/172R TAM-2/172K. AZT concentration [nm] AZT concentration [nm] MgCl 2 2.5K 2.5K 5K 2.5K 5K 2.5K K 5K 2.5K 5K 2.5K 50 2.

172R 172K TAM-2/172R TAM-2/172K. AZT concentration [nm] AZT concentration [nm] MgCl 2 2.5K 2.5K 5K 2.5K 5K 2.5K K 5K 2.5K 5K 2.5K 50 2. 5 5 5 5 A MgCl 2 172R 172K TAM-2/172R TAM-2/172K AZT concentration [nm] B 172R 172K TAM-2/172R TAM-2/172K AZT concentration [nm] ATP + ATP - Supplemental Figure 1. Primer extension of HIV-1 RT polymorphisms

More information

Table S1: Kinetic parameters of drug and substrate binding to wild type and HIV-1 protease variants. Data adapted from Ref. 6 in main text.

Table S1: Kinetic parameters of drug and substrate binding to wild type and HIV-1 protease variants. Data adapted from Ref. 6 in main text. Dynamical Network of HIV-1 Protease Mutants Reveals the Mechanism of Drug Resistance and Unhindered Activity Rajeswari Appadurai and Sanjib Senapati* BJM School of Biosciences and Department of Biotechnology,

More information

Antibacterials and Antivirals

Antibacterials and Antivirals Structure of a Bacterium: Antibacterials and Antivirals Capsule: protective layer made up of proteins, sugars and lipids Cell wall: provides the bacteria with its shape and structure Cell membrane: permeable

More information

Clinical Management of HIV Drug Resistance

Clinical Management of HIV Drug Resistance Viruses 2011, 3, 347-378; doi:10.3390/v3040347 OPEN ACCESS viruses ISSN 1999-4915 www.mdpi.com/journal/viruses Review Clinical Management of HIV Drug Resistance Karoll J. Cortez and Frank Maldarelli *

More information

3.2 Ligand-Binding at Nicotinic Acid Receptor Subtypes GPR109A/B

3.2 Ligand-Binding at Nicotinic Acid Receptor Subtypes GPR109A/B 3.2 Ligand-Binding at Nicotinic Acid Receptor Subtypes GPR109A/B 3.2.1 Characterization of the Ligand Binding Site at GPR109A Receptor Ligands of GPR109A Receptor are Carboxylic Acids Nicotinic acid (pyridine-3-carboxylic

More information

5/6/17. Diseases. Disease. Pathogens. Domain Bacteria Characteristics. Bacteria Viruses (including HIV) Pathogens are disease-causing organisms

5/6/17. Diseases. Disease. Pathogens. Domain Bacteria Characteristics. Bacteria Viruses (including HIV) Pathogens are disease-causing organisms 5/6/17 Disease Diseases I. II. Bacteria Viruses (including HIV) Biol 105 Chapter 13a Pathogens Pathogens are disease-causing organisms Domain Bacteria Characteristics 1. Domain Bacteria are prokaryotic.

More information

Viral reproductive cycle

Viral reproductive cycle Lecture 29: Viruses Lecture outline 11/11/05 Types of viruses Bacteriophage Lytic and lysogenic life cycles viruses viruses Influenza Prions Mad cow disease 0.5 µm Figure 18.4 Viral structure of capsid

More information

Unit 2: Lesson 2 Case Studies: Influenza and HIV LESSON QUESTIONS

Unit 2: Lesson 2 Case Studies: Influenza and HIV LESSON QUESTIONS 1 Unit 2: Lesson 2 Case Studies: Influenza and HIV LESSON QUESTIONS What steps are involved in viral infection and replication? Why are some kinds of influenza virus more deadly than others? How do flu

More information

Chymotrypsin Lecture. Aims: to understand (1) the catalytic strategies used by enzymes and (2) the mechanism of chymotrypsin

Chymotrypsin Lecture. Aims: to understand (1) the catalytic strategies used by enzymes and (2) the mechanism of chymotrypsin Chymotrypsin Lecture Aims: to understand (1) the catalytic strategies used by enzymes and (2) the mechanism of chymotrypsin What s so great about enzymes? They accomplish large rate accelerations (10 10-10

More information

1918 Influenza; Influenza A, H1N1. Basic agent information. Section I- Infectious Agent. Section II- Dissemination

1918 Influenza; Influenza A, H1N1. Basic agent information. Section I- Infectious Agent. Section II- Dissemination 1918 Influenza; Influenza A, H1N1 Basic agent information Section I- Infectious Agent Risk Group: - RG3 Synonym or Cross reference: - Spanish Flu - 1918 Flu - El Grippe Characteristics: - SELECT AGENT

More information

Emerging CMV Resistance Profile for CMX001

Emerging CMV Resistance Profile for CMX001 Emerging CMV Resistance Profile for CMX001 International Conference on Antiviral Research May 15, 2013 Randall Lanier, PhD Forward Looking Statements These slides and the accompanying oral presentation

More information

Abstract #8 15th EU Meeting on HIV & Hepatitis (7-9 June 2017)

Abstract #8 15th EU Meeting on HIV & Hepatitis (7-9 June 2017) Epidemiological study of Doravirine associated resistance mutations in HIV-1- infected treatment-naïve patients from two large databases in France and Italy Anne-Genevieve Marcelin, Maria Mercedes Santoro,

More information

Introduction to the Impact of Resistance in Hepatitis C

Introduction to the Impact of Resistance in Hepatitis C Introduction to the Impact of Resistance in Hepatitis C Sponsored by AbbVie 2/1/2017 Presented by Sammy Saab, MD, MPH, FACG, AGAF, FAASLD February 1 st, 2017 1 AbbVie disclosures This is an Abbvie sponsored

More information

Pullman, WA, 99164, USA

Pullman, WA, 99164, USA IDENTIFYING INTERACTION SITES IN "RECALCITRANT" PROTEINS: PREDICTED PROTEIN AND RNA BINDING SITES IN REV PROTEINS OF HIV-1 AND EIAV AGREE WITH EXPERIMENTAL DATA MICHAEL TERRIBILINI 1,3, JAE-HYUNG LEE 1,3,

More information

Helminth worm, Schistosomiasis Trypanosomes, sleeping sickness Pneumocystis carinii. Ringworm fungus HIV Influenza

Helminth worm, Schistosomiasis Trypanosomes, sleeping sickness Pneumocystis carinii. Ringworm fungus HIV Influenza Helminth worm, Schistosomiasis Trypanosomes, sleeping sickness Pneumocystis carinii Ringworm fungus HIV Influenza Candida Staph aureus Mycobacterium tuberculosis Listeria Salmonella Streptococcus Levels

More information

Allergy and Immunology Review Corner: Chapter 13 of Immunology IV: Clinical Applications in Health and Disease, by Joseph A. Bellanti, MD.

Allergy and Immunology Review Corner: Chapter 13 of Immunology IV: Clinical Applications in Health and Disease, by Joseph A. Bellanti, MD. Allergy and Immunology Review Corner: Chapter 13 of Immunology IV: Clinical Applications in Health and Disease, by Joseph A. Bellanti, MD. Chapter 13: Mechanisms of Immunity to Viral Disease Prepared by

More information

Virion Genome Genes and proteins Viruses and hosts Diseases Distinctive characteristics

Virion Genome Genes and proteins Viruses and hosts Diseases Distinctive characteristics Hepadnaviruses Virion Genome Genes and proteins Viruses and hosts Diseases Distinctive characteristics Hepatitis viruses A group of unrelated pathogens termed hepatitis viruses cause the vast majority

More information

Diagnostic Methods of HBV and HDV infections

Diagnostic Methods of HBV and HDV infections Diagnostic Methods of HBV and HDV infections Zohreh Sharifi,ph.D Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine Hepatitis B-laboratory diagnosis Detection

More information

Evolutionary origin of correlated mutations in protein sequence alignments

Evolutionary origin of correlated mutations in protein sequence alignments Evolutionary origin of correlated mutations in protein sequence alignments Alexandre V. Morozov Department of Physics & Astronomy and BioMaPS Institute for Quantitative Biology, Rutgers University morozov@physics.rutgers.edu

More information

The major histocompatibility complex (MHC) is a group of genes that governs tumor and tissue transplantation between individuals of a species.

The major histocompatibility complex (MHC) is a group of genes that governs tumor and tissue transplantation between individuals of a species. Immunology Dr. John J. Haddad Chapter 7 Major Histocompatibility Complex The major histocompatibility complex (MHC) is a group of genes that governs tumor and tissue transplantation between individuals

More information

Immune pressure analysis of protease and reverse transcriptase genes of primary HIV-1 subtype C isolates from South Africa

Immune pressure analysis of protease and reverse transcriptase genes of primary HIV-1 subtype C isolates from South Africa African Journal of Biotechnology Vol. 10(24), pp. 4784-4793, 6 June, 2011 Available online at http://www.academicjournals.org/ajb DOI: 10.5897/AJB10.560 ISSN 1684 5315 2011 Academic Journals Full Length

More information

Supplementary information. MARCH8 inhibits HIV-1 infection by reducing virion incorporation of envelope glycoproteins

Supplementary information. MARCH8 inhibits HIV-1 infection by reducing virion incorporation of envelope glycoproteins Supplementary information inhibits HIV-1 infection by reducing virion incorporation of envelope glycoproteins Takuya Tada, Yanzhao Zhang, Takayoshi Koyama, Minoru Tobiume, Yasuko Tsunetsugu-Yokota, Shoji

More information

Animal hosts Natural host Laboratory animals Rabbits Mice Rats Hamsters Newborn or suckling rodents Animal models for viral pathogenesis 4 Growth of v

Animal hosts Natural host Laboratory animals Rabbits Mice Rats Hamsters Newborn or suckling rodents Animal models for viral pathogenesis 4 Growth of v Principles of Virology Department of Molecular Genetics & Microbiology Univ ersity of Florida, Gainesv ille, FL 1 Outline Virus cultivation Assay of viruses Virus genetics 2 Virus isolation Evidence of

More information

Virus Structure. Characteristics of capsids. Virus envelopes. Virion assembly John Wiley & Sons, Inc. All rights reserved.

Virus Structure. Characteristics of capsids. Virus envelopes. Virion assembly John Wiley & Sons, Inc. All rights reserved. Virus Structure Characteristics of capsids Virus envelopes Virion assembly Capsids package viral genomes and transmit them to a new host cell Capsid rigid, symmetrical container composed of viral protein

More information

2 nd Line Treatment and Resistance. Dr Rohit Talwani & Dr Dave Riedel 12 th June 2012

2 nd Line Treatment and Resistance. Dr Rohit Talwani & Dr Dave Riedel 12 th June 2012 2 nd Line Treatment and Resistance Dr Rohit Talwani & Dr Dave Riedel 12 th June 2012 Overview Basics of Resistance Treatment failure Strategies to manage treatment failure Mutation Definition: A change

More information

Lecture 2: Virology. I. Background

Lecture 2: Virology. I. Background Lecture 2: Virology I. Background A. Properties 1. Simple biological systems a. Aggregates of nucleic acids and protein 2. Non-living a. Cannot reproduce or carry out metabolic activities outside of a

More information

LS1a Fall 06 Problem Set #4

LS1a Fall 06 Problem Set #4 LS1a Fall 06 Problem Set #4 Due Friday 10/27 at noon in your TF s drop box on the 2 nd floor of the Science Center all questions including the (*extra*) one should be turned in 1. To further investigate

More information

Cbl ubiquitin ligase: Lord of the RINGs

Cbl ubiquitin ligase: Lord of the RINGs Cbl ubiquitin ligase: Lord of the RINGs Not just quite interesting - really interesting! A cell must be able to degrade proteins when their activity is no longer required. Many eukaryotic proteins are

More information

Dedicated to Preventing and Treating Life-Threatening Viral Infections. Randall Lanier Vice President, Biology

Dedicated to Preventing and Treating Life-Threatening Viral Infections. Randall Lanier Vice President, Biology Dedicated to Preventing and Treating Life-Threatening Viral Infections Randall Lanier Vice President, Biology Adenovirus: Epidemiology and Treatment Options Allogeneic hematopoietic cell transplant (allo

More information

DIFFERENTIAL IMPACT OF HIV-1 PROTEASE INHIBITORS ON SUBSETS OF CD4+ T-LYMPHOCYTES

DIFFERENTIAL IMPACT OF HIV-1 PROTEASE INHIBITORS ON SUBSETS OF CD4+ T-LYMPHOCYTES DIFFERENTIAL IMPACT OF HIV-1 PROTEASE INHIBITORS ON SUBSETS OF CD4+ T-LYMPHOCYTES By CHRISTINA GAVEGNANO A THESIS PRESENTED TO THE GRADUATE SCHOOL OF THE UNIVERSITY OF FLORIDA IN PARTIAL FULFILLMENT OF

More information

HCV NS3 Protease Drug Resistance

HCV NS3 Protease Drug Resistance test code: cpt code: 10000 87902 category: Infectious Disease HCV genotype 1a CODON Glecaprevir 1a Grazoprevir 1a Paritaprevir 1a Simeprevir 1a Voxilaprevir 1a V36A S 13 R 10 Comment V36C V36G V36I V36L

More information

Prevalence of Transmitted Drug Resistance Mutations among Naive HIV-infected patients ( ) in Northwest Spain

Prevalence of Transmitted Drug Resistance Mutations among Naive HIV-infected patients ( ) in Northwest Spain Prevalence of Transmitted Drug Resistance Mutations among Naive HIV-infected patients (2014-2016) in Northwest Spain Berta Pernas 1, Andrés Tabernilla 1, Marta Grandal 1, Angelina Cañizares 2, Sofía Ortún

More information

Peptide hydrolysis uncatalyzed half-life = ~450 years HIV protease-catalyzed half-life = ~3 seconds

Peptide hydrolysis uncatalyzed half-life = ~450 years HIV protease-catalyzed half-life = ~3 seconds Uncatalyzed half-life Peptide hydrolysis uncatalyzed half-life = ~450 years IV protease-catalyzed half-life = ~3 seconds Life Sciences 1a Lecture Slides Set 9 Fall 2006-2007 Prof. David R. Liu In the absence

More information

Phenylketonuria (PKU) Structure of Phenylalanine Hydroxylase. Biol 405 Molecular Medicine

Phenylketonuria (PKU) Structure of Phenylalanine Hydroxylase. Biol 405 Molecular Medicine Phenylketonuria (PKU) Structure of Phenylalanine Hydroxylase Biol 405 Molecular Medicine 1998 Crystal structure of phenylalanine hydroxylase solved. The polypeptide consists of three regions: Regulatory

More information